AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29718390
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg rifampicin (reference arm)
Trial: 29718390
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg rifampicin
Trial: 29718390
Drug: 25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg rifampicin
Trial: 29718390
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg rifampicin
Trial: 29718390
Drug: 35 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg/kg rifampicin
Trial: 29718390
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg rifampicin
Trial: 29718390
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg rifampicin (predicted)
Trial: 29720163
Drug: Pre-referral rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-referral rectal artesunate treatment
Trial: 29720224
Drug: Non-TC chemotherapy
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-TC chemotherapy regimens
Trial: 29720277
Drug: Optimal PEEP
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal PEEP titration
Trial: 29720487
Drug: First-line therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line therapy for PMBCL
Trial: 29720734
Drug: G-CSF, cladribine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF, cladribine, high-dose cytarabine, and dose-escalated mitoxantrone (GCLAM)
Trial: 29721378
Drug: Vemurafenib (BRAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vemurafenib (BRAF inhibitor) and aldesleukin (interleukin-2)
Trial: 29722789
Drug: Weighted prevalence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weighted prevalence of regorafenib toxicity profile and dose reduction
Trial: 29722836
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake ≥250-299 μg/d in 7- to 10-y-old children
Trial: 29722836
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake ≥300-399 μg/d in 11- to 14-y-old children
Trial: 29722838
Drug: Maternal intake
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal intake of total vitamin D (≥13.6 µg/d)
Trial: 29722851
Drug: Calcium-to-magnesium ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-to-magnesium ratio (Ca:Mg) intake, tertile 2
Trial: 29722851
Drug: Calcium-to-magnesium ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-to-magnesium ratio (Ca:Mg) intake, tertile 3
Trial: 29722851
Drug: Calcium-to-magnesium ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-to-magnesium ratio (Ca:Mg) intake, tertile 3 (stratified by race)
Trial: 29723161
Drug: Metreleptin treatment
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin treatment for 14 days (initiation cohort)
Trial: 29723161
Drug: Metreleptin treatment
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin treatment for 6 months on an ad libitum diet (initiation cohort)
Trial: 29723397
Drug: Dasatinib 50 mg
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib 50 mg daily
Trial: 29723689
Drug: Drugs not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs not toxic to MH cells
Trial: 29724397
Drug: GFF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF MDI 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) twice daily for 7 days with VHC
Trial: 29724397
Drug: GFF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF MDI 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) twice daily for 7 days without VHC
Trial: 29726923
Drug: Brontictuzumab administered
RxNorm normalized name: Brontictuzumab
DrugBank: Brontictuzumab (DB12737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brontictuzumab administered intravenously at 1.5 mg/kg every 3 weeks (Q3W) during expansion phase.
Trial: 29726923
Drug: Brontictuzumab administered
RxNorm normalized name: Brontictuzumab
DrugBank: Brontictuzumab (DB12737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brontictuzumab administered intravenously at various dose levels during dose escalation.
Trial: 29727073
Drug: Ketamine infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusions (0.5 mg/kg)
Trial: 29728755
Drug: Remifentanil (2.68-3.11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (2.68-3.11 µg/kg) co-administered with propofol (3 mg/kg)
Trial: 29730377
Drug: Dexamethasone delivery
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone delivery adjunctive to standard endovascular revascularization
Trial: 29730615
Drug: High-dose medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose medical exercise therapy (MET) - 70-90 minutes per session, 3 times a week for 12 weeks (total of 36 sessions)
Trial: 29730615
Drug: Low-dose medical
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose medical exercise therapy (MET) - 20-30 minutes per session, 3 times a week for 12 weeks (total of 36 sessions)
Trial: 29731369
Drug: Tailored frequency-escalated
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored frequency-escalated primary prophylaxis with standard half-life recombinant factor VIII (SHL-rFVIII), starting at 50 IU/kg once weekly, escalating in frequency and dosage as needed.
Trial: 29731779
Drug: NSC-mediated therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSC-mediated therapy
Trial: 29733524
Drug: Veliparib extended-release
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib extended-release (ER) 800 mg once daily or 600 mg twice daily
Trial: 29733524
Drug: Veliparib extended-release
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib extended-release (ER) 200 mg (fasting)
Trial: 29733524
Drug: Veliparib extended-release
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib extended-release (ER)
Trial: 29733771
Drug: Birabresib 80
RxNorm normalized name: Birabresib
DrugBank: Birabresib (DB15189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birabresib 80 mg once daily (cohort A)
Trial: 29733771
Drug: Birabresib 100
RxNorm normalized name: Birabresib
DrugBank: Birabresib (DB15189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birabresib 100 mg for 7 consecutive days (cohort B)
Trial: 29733771
Drug: Birabresib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birabresib (80 mg once daily)
Trial: 29733771
Drug: Birabresib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birabresib (80 mg once daily) in patients with NMC
Trial: 29734948
Drug: Aerosolized inhaled
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP) at 800 μg twice daily for 1 week
Trial: 29734948
Drug: Aerosolized inhaled
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP) at 200 μg twice daily for 1 week
Trial: 29734948
Drug: Aerosolized inhaled
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP) at 400 μg twice daily for 1 week
Trial: 29734948
Drug: Aerosolized inhaled
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP) at 600 μg twice daily for 1 week
Trial: 29734953
Drug: Amisulpride (dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (dopamine D2/3 receptor antagonist) treatment for 6 weeks
Trial: 29734990
Drug: PAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAP therapy for 6 weeks
Trial: 29734990
Drug: Exosomes isolated
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exosomes isolated before PAP therapy
Trial: 29734990
Drug: Exosomes isolated
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exosomes isolated after PAP therapy
Trial: 29735299
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitor (TKI) therapy discontinuation
Trial: 29735299
Drug: Imatinib as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib as first-line treatment
Trial: 29736468
Drug: Standard method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard method (empirical fluid administration)
Trial: 29736473
Drug: 4 cups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cups of instant regular coffee daily
Trial: 29736473
Drug: 4 cups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cups of a coffee-like placebo beverage daily
Trial: 29737243
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of paracetamol
Trial: 30583256
Drug: Desvenlafaxine (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (50-100 mg/day)
Trial: 29739356
Drug: 3 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of consolidation chemotherapy before TME, followed by 5 cycles of adjuvant chemotherapy (experimental arm)
Trial: 29739356
Drug: 8 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 cycles of adjuvant chemotherapy (control arm)
Trial: 29739389
Drug: Higher-protein group
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-protein group (median protein intake 4.3 g/kg/d)
Trial: 29739389
Drug: Lower-protein group
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-protein group (median protein intake 3.7 g/kg/d)
Trial: 29739393
Drug: Nursing home
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nursing home treatment for dehydration or bacterial infections
Trial: 29739393
Drug: Hospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital treatment for dehydration or bacterial infections
Trial: 29739754
Drug: Dexpramipexole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexpramipexole (150 mg orally twice daily)
Trial: 29740788
Drug: Provider education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider education on guidelines for the appropriate treatment of ARIs
Trial: 29741298
Drug: Bevacizumab pre-treatment
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab pre-treatment in mice
Trial: 29741697
Drug: l-lysine (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-lysine (10, 13, 16, and 18 mg · kg-1 · d-1)
Trial: 29741697
Drug: l-tryptophan (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-tryptophan (0.5, 1, 1.5, and 2 mg · kg-1 · d-1)
Trial: 29742009
Drug: Neoadjuvant dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant dose-dense gemcitabine and cisplatin (ddGC)
Trial: 29742471
Drug: Initial antibiotic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antibiotic therapy (IAT) received ≤ 48 h post-initiation, mean duration 8.8 days, 62.5% received monotherapy.
Trial: 29743148
Drug: Secondary cytoreductive
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary cytoreductive surgery followed by platinum-based chemotherapy
Trial: 29745476
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy with prasugrel/ticagrelor at discharge
Trial: 29746639
Drug: BCAA diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA diet (1.03 g · kg-1 · d-1)
Trial: 29746639
Drug: EAA diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAA diet (1.23 g · kg-1 · d-1)
Trial: 29746639
Drug: SUF diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUF diet (1.75 g · kg-1 · d-1)
Trial: 29746639
Drug: NEAA diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEAA diet (1.75 g · kg-1 · d-1)
Trial: 29746639
Drug: BASE diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BASE diet (0.8 g · kg-1 · d-1)
Trial: 29747074
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day of zinc from day +5 to day +100 after transplant
Trial: 29747670
Drug: Jiedu Tongluo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiedu Tongluo granules (JDTLG) with conventional treatment
Trial: 29747670
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with conventional treatment
Trial: 29747700
Drug: Myo-inositol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-inositol (2 g, twice per day) for three months followed by myo-inositol plus alpha-lactalbumin (50 mg, twice per day) for three months
Trial: 29747700
Drug: Myo-inositol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-inositol (2 g, twice per day) for three months
Trial: 29747700
Drug: Myo-inositol plus
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myo-inositol plus alpha-lactalbumin (50 mg, twice per day)
Trial: 29747838
Drug: High-Dose Ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-Dose Ferric Carboxymaltose
Trial: 29748160
Drug: Activity tracking
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity tracking with weekly review of self-reports and activity information.
Trial: 29748160
Drug: Activity tracking
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity tracking and self-reporting with weekly review.
Trial: 29748344
Drug: Data collection
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data collection and abstraction of patient characteristics, diagnostic testing, treatments, and in-hospital outcomes.
Trial: 29748435
Drug: End-of-treatment PET
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-of-treatment PET (negative Deauville 1-3)
Trial: 29748435
Drug: End-of-treatment PET
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-of-treatment PET (positive Deauville 4-5)
Trial: 29748444
Drug: Bendamustine (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine (90 mg/m²) plus Rituximab
Trial: 29750067
Drug: Non-vitamin-K-antagonist oral
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-vitamin-K-antagonist oral anticoagulant (NOAC) treatment
Trial: 29750067
Drug: Vitamin-K-antagonist (VKA)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-K-antagonist (VKA) treatment
Trial: 29750396
Drug: Cabazitaxel at
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel at a starting dose of 20 mg/m², escalated to a maximum tolerated dose (MTD) of 30 mg/m².
Trial: 29750396
Drug: Cabazitaxel at
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel at a dose of 35 mg/m².
Trial: 29750699
Drug: Closed-loop-assisted goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop-assisted goal-directed fluid therapy (GDFT) with a baseline crystalloid infusion of 3 ml/kg/h and additional 100 ml fluid boluses of crystalloid or colloid.
Trial: 29750699
Drug: Closed-loop-assisted goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop-assisted goal-directed fluid therapy (GDFT)
Trial: 29750747
Drug: Clofarabine at
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clofarabine at a dose of 50 mg/m/d for 5 days
Trial: 29750766
Drug: Maternal viral
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal viral load >1,000,000 copies/mL at delivery
Trial: 29751792
Drug: gemcitabine-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine-based chemotherapy
Trial: 29752199
Drug: R-GemOx regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-GemOx regimen (rituximab 375 mg/m2, gemcitabine, and oxaliplatin) administered intravenously as first-line treatment.
Trial: 29752199
Drug: R-GemOx regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-GemOx regimen (rituximab 375 mg/m2, gemcitabine, and oxaliplatin) administered intravenously.
Trial: 29752388
Drug: PCI plus
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI plus optimal medical therapy (OMT)
Trial: 29753517
Drug: Liberal fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal fluids approach (50 to 75 mL/kg during the first 6 hours)
Trial: 29753517
Drug: Restrictive fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluids approach (≤30 mL/kg)
Trial: 29754661
Drug: State-of-the-art rate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: State-of-the-art rate or rhythm control drug therapy
Trial: 29755707
Drug: Oral colistin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral colistin for 14 days
Trial: 29756206
Drug: Oral pimasertib
RxNorm normalized name: capivasertib Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pimasertib (once daily for 5 days on/2 days off or twice daily continuously) combined with weekly gemcitabine (1,000 mg/m2)
Trial: 29756206
Drug: Oral pimasertib
RxNorm normalized name: capivasertib Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pimasertib
Trial: 29756206
Drug: Weekly gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly gemcitabine (1,000 mg/m2)
Trial: 29756531
Drug: Pediatric Malaria
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric Malaria Vaccine (GSK/PATH-MVI RTS,S)
Trial: 29756750
Drug: Remifentanil IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil IV infusion of 0.005 µg/kg/min
Trial: 29756750
Drug: Remifentanil IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil IV infusion of 0.05 µg/kg/min
Trial: 29756750
Drug: Remifentanil IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil IV infusion of 0.1 µg/kg/min
Trial: 29756750
Drug: Remifentanil IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil IV infusion of 0.15 µg/kg/min
Trial: 29757399
Drug: DHEAS ≥40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEAS ≥40 µg/dL
Trial: 29759747
Drug: Average CF
RxNorm normalized name: californium Cf-249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average CF categories of 0 to 10 g
Trial: 29759747
Drug: Average CF
RxNorm normalized name: californium Cf-249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average CF categories of 10 to 20 g
Trial: 29759747
Drug: Average CF
RxNorm normalized name: californium Cf-249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average CF categories of >20 g
Trial: 29759747
Drug: CF of
RxNorm normalized name: Rovin-Cf OF Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF of 6.5 to 10.3 g
Trial: 29760763
Drug: Vortioxetine (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (5, 10, or 20 mg)
Trial: 29761174
Drug: Elbasvir/grazoprevir (EBR/GZR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir/grazoprevir (EBR/GZR) 50 mg/100 mg once daily for 12 weeks
Trial: 29761903
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ABC294640 (sphingosine kinase 2 inhibitor) and ABT-199 (Bcl-2 inhibitor)
Trial: 29761903
Drug: ABT-199 (Bcl-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-199 (Bcl-2 inhibitor)
Trial: 29761903
Drug: ABC294640 (sphingosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC294640 (sphingosine kinase 2 inhibitor)